CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group Performance Status of 0 or 1； 2. Expected survival time ≥12 weeks; 3. Adequate hematological, renal and liver function; 4. Subjects understand and voluntarily sign the informed consent form. Key Exclusion Criteria: 1. Positive for any of the following etiological tests: HIV, HBV, HCV, TPPA ; 2. Cyclophosphamide or fludarabine is contraindicated for subjects ; 3. Active central nervous system (CNS) involvement by malignancy； 4. Active infection.